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Abstract 
Natural products play a pivotal role in medicine especially in the cancer arena. Many 
drugs that are currently used in cancer chemotherapy originated from or were inspired by 
nature. Jerantinine B (JB) is one of seven novel Aspidosperma indole alkaloids isolated 
from the leaf extract of Tabernaemontana corymbosa. Preliminary antiproliferative 
assays revealed that JB and JB acetate significantly inhibited growth and colony 
formation, accompanied by time- and dose-dependent apoptosis induction in human 
cancer cell lines. JB significantly arrested cells at G2/M cell cycle phase, potently 
inhibiting tubulin polymerisation. Polo-like kinase 1 (PLK1; an early trigger for the 
G2/M transition) was also dose-dependently inhibited by JB (IC50 1.5μM). Furthermore, 
JB provoked significant increases in reactive oxygen species (ROS). Annexin V+ cell 
populations, dose-dependent accumulation of cleaved-PARP and caspase 3/7 activation, 
and reduced Bcl-2 and Mcl-1 expression confirm apoptosis induction. Preclinical in silico 
biopharmaceutical assessment of JB calculated rapid absorption and bioavailability 
>70%. Doses of 8-16 mg/kg JB were predicted to maintain unbound plasma 
concentrations >GI50 values in mice during efficacy studies. These findings advocate 
continued development of JB as a potential chemotherapeutic agent. 
 
Keywords: Natural products. Cell cycle. Tubulin. PLK1. Reactive oxygen species. 
Apoptosis. 
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1. Introduction 
Natural products (NP) have historically been used in the treatment of many diseases and 
continue to provide pharmacological agents used in pharmaceutical, biological and 
medical fields [1]. NPs are known for their structural diversity and have played 
inspirational roles in drug discovery [2];  50% of pharmaceuticals are derived from 
natural sources [3]. Thus it is important to pursue NP drug discovery to identify novel 
molecules from fragile rainforest habitats which may possess anticancer activity. Success 
in this field has led to the use of microtubule targeting agents (MTAs) in cancer 
chemotherapy. Vincristine and vinblastine, isolated from Catharanthus roseus, and taxol, 
isolated from the Pacific Yew, Taxus brevifolia, remain integral to the treatment of 
haematological and intractable solid cancers [4]. MTAs can act as stabilising agents (e.g. 
paclitaxel), promoting microtubule assembly, or destabilising agents (e.g. vincristine) to 
promote microtubule disassembly, altering microtubule dynamicity by binding to tubulin 
dimers [5]. Efficacy in the treatment of cancer arises from their ability to bind to tubulin 
and specifically inhibit mitosis [6, 7]. The cell cycle is governed by a rigorous system of 
checkpoints that consists of cyclin-dependent kinase (CDK)-cyclin complexes that allow 
progression from one cell cycle phase to the next [8, 9, 10]. Taxanes and vinca alkaloids 
arrest cell cycle at G2/M, affecting levels of cyclin B1 [8, 11, 12]. In 2008, seven novel 
Aspidosperma indole alkaloids were isolated, jerantinines A–G, from a leaf extract of 
Malayan plant Tabernaemontana corymbosa [13]. Jerantinine A (JA) evoked potent 
inhibitory activity against human-derived cancer cells causing profound G2/M block and 
clear inhibition of tubulin polymerisation [8]. Similarly, jerantinine E (JE) was shown to 
disrupt microtubules in PtK2 kidney cells [14]. Herein, we report in vitro biological 
evaluation of JB, a structural analogue of JA. In vitro activities of JB and its acetate 
derivative have been examined in human-derived colorectal (HCT-116), breast (MCF-7), 
lung (A549), pancreatic (MIA PaCa-2), vincristine resistant (VR) HCT-116 carcinoma 
cell lines and MRC5 fibroblasts by MTT assays. Cell counts, clonogenic assays, cell 
cycle analyses, confocal microscopy, annexin-V/PI apoptosis, caspase 3/7 activity assays 
and Western blots have been undertaken. Tubulin polymerisation, PLK1 activity and 
generation of reactive oxygen species (ROS) were also assessed in efforts to elucidate 
mechanisms of action of JB. In addition, the physicochemical and pharmacokinetic 
properties of JB were assessed in silico. 
 
2. Materials and methods 
 
2.1 Isolation and characterisation of JB and JBA 
JB (Fig. 1) was isolated from Tabernaemontana corymbosa leaf extract. JBA (Fig. 1) was 
prepared by dissolving 20mg (0.050mM) in 1mL of pyridine and 1mL acetic anhydride. 
The mixture was stirred for 20 min. Water (10mL) was added, and pH adjusted to 9 using 
10% Na2CO3 solution [13]. 
 
2.2 Agent stocks 
JB and JBA were provided as solids and reconstituted with DMSO to yield 
concentrations of 10mM. Stocks were stored as 10µL aliquots at -80oC protected from 
light. 
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2.3 Cell culture 
Cells were passaged twice weekly upon reaching 70-80% confluency. Cells were sub-
cultured in RPMI 1640 medium containing sodium bicarbonate supplemented (2g/L), L-
glutamine (0.3g/L) and 10% heat-inactivated foetal bovine serum. 
 
2.4 Generation of vincristine resistance 
A variant HCT 116 cell line was established with acquired resistance to vincristine 
following continued exposure (>6 months) of cells to escalating concentrations of 
vincristine. Resistant subclones (VR) are those surviving and proliferating in the presence 
of 2μM vincristine.  
 
2.5 MTT assay 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, adapted 
from Mosmann [15], was used to assess the ability of test agents to inhibit cell growth 
and/or evoke cytotoxicity [16].  MTT assays were performed at the time of agent addition 
(T zero) and following 72h exposure of cells to test agents, as previously described [8]. 
 
2.6 Cell counting assay  
Cell counts were performed to substantiate MTT assay results. Cells (2×104 cells/well) 
were seeded in 6 well plates are incubated overnight before treatment with JB at 0.1, 0.2, 
0.5 and 1µM (72h). Cells were harvested and counted by haemocytometer.   
 
2.7 Clonogenic assay 
The clonogenic cell survival test measures the ability of a single cell to survive brief 
exposure to test agent and maintain proliferative potential to form progeny colonies 
[17.18].  The assay was performed as previously described [8]. 
 
2.8 Cell cycle analysis 
Cell cycle analysis was carried according to Nicoletti et al (1991) [19]. Cells were seeded 
in cell culture dishes at densities of 3-5×105 cells/dish in 10mL medium. Following 
treatment, cells were harvested and pelleted by centrifugation then re-suspended in 0.5-
1mL fluorochrome solution (50µg/mL propidium iodide (PI), 0.1mg/mL ribonuclease A, 
0.1% v/v Triton X-100, and 0.1% w/v sodium citrate in dH2O). Cells were stored 
overnight in the dark at 4oC. Cell cycle analyses were performed on a Beckman Coulter 
FC500 flow cytometer. EX- PO32 software was used to analyse data. 
 
2.9 Tubulin polymerisation assay 
The tubulin polymerisation assay [20, 21, 22] was conducted in 96-well plates according 
to manufacturer’s (Cytoskeleton, Inc) instructions. Incubations included 1mM EGTA, 
1mM MgCl2, tubulin buffer: 80mM Na-PIPES (pH 6.9), test compound (JB, 1 and 5μM; 
paclitaxel and nocodazole, 5μM) and HTS-tubulin (4mg/mL). Paclitaxel (microtubule 
stabiliser) and nocodazole (tubulin polymerisation inhibitor) were included as positive 
and negative controls respectively: Tubulin polymerisation was triggered by addition of 
1mM GTP and carried out at 37°C; fluorescence absorbance at 340nm was measured 
over 1.15h. Scattered light is directly proportional to microtubule polymer concentration. 
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2.10 Annexin V – FITC and propidium iodide apoptosis assay 
Reagents used were Annexin V-FITC Ab, 1× annexin binding buffer (1:10 dilution 10× 
annexin binding buffer in dH2O), and PI solution (50µg/mL in PBS). Cells (1×10
5 
cells/well) were seeded in 6 well plates are incubated overnight before treatment with JB 
at 1× and 2×GI50 (24, 48 and 72h). Cells were trypsinised and collected in FACS tubes 
then kept on ice for 10 min. Annexin-V-FITC (5μL) plus 100μL 1× annexin-V buffer 
were added to cells after centrifugation. After 15 min incubation in the dark at room 
temperature, PI (10μL; 50μg/mL in PBS) plus 400μL annexin-V buffer were added. 
Samples were protected from light and kept on ice for 10 min before analysis on a 
Beckman Coulter FC500 flow cytometer. EX- PO32 software was used to analyse data. 
 
2.11 Caspase-3/7 activity assay 
The Apo-ONE® Homogeneous caspase 3/7 assay (Promega) was used to determine 
caspase activity. Cells (5×103 per well) were seeded in 96 well opaque white or black cell 
culture plates and incubated overnight at 37°C. JB or vincristine (1×GI50; 48h exposure) 
was introduced. Apo-ONE® caspase-3/7 reagent was added to each well with gentle 
mixing (300–500rpm) for at least 30 seconds. Plates were incubated for 30 min at room 
temperature. Well fluorescence was measured using an EnVision multilabel plate reader 
(PerkinElmer) at wavelengths between 499nm and 521nm. 
 
2.12 Western blots 
Western blotting was carried out as described [23]. Cells were seeded in dishes (100×20 
mm) at a density of 1-2 x 106 per dish, allowed 24 hours to attach, and exposed to 1×GI50 
and 2×GI50 JB. Following exposure, cell lysates were prepared and protein concentrations 
evaluated by Bradford assay [24]; 50µg protein per sample were separated by PAGE. 
Whole PARP, cleaved PARP, Mcl-1, Bcl-2, PLK1 and P glycoprotein (Pgp) 1o Abs were 
purchased from Cell Signaling Technologies. β-Tubulin 1o Ab (TUBB) was bought from 
Source BioScience. Anti-rabbit and anti-mouse immunoglobulin G (IgG) horseradish 
peroxidase-conjugated 2o Abs were obtained from Dako. Densitometric analyses of 
Western blots were performed using Image J.  
 
2.13 Confocal microscopy 
Confocal imaging was performed as previously described [25]. Procedures were 
performed at room temperature. Cells were fixed in formaldehyde (3.7 % in PBS; 10–15 
min) then permeabilised by PBT (PBS + 0.1% Triton X-100; 2–3 min). Blocking agent 
(PBT + 1% BSA; 1h) was used to prevent binding non-specific protein binding. Cells 
were incubated with 1° Ab (monoclonal anti α-tubulin Ab, VWR International Ltd.; 2h), 
washed with PBT before incubation in the dark with 2° Ab for 1h. Cells were incubated 
with DNA binding dye (DRAQ5) for 5 min in the dark; a Zeiss LSM510 Meta confocal 
microscope was used to capture images. 
 
2.14 Detection of reactive oxygen species 
The ROS-Glo™ H2O2 luminescent assay is a sensitive, rapid, homogeneous assay that 
measures H2O2 levels directly in cell culture. Cells (5x10
3) were seeded in 96-well white 
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opaque plates in 80μL medium, incubated overnight and then treated with JB or 
vincristine for 24h. H2O2 substrate was added to incubates for 6h. The ROS-Glo™ 
detection solution was introduced (100μL) and plates incubated for 20 min at room 
temperature. Relative luminescence was measured using an EnVision multilabel plate 
reader (PerkinElmer). 
 
2.15 PLK1 assay 
PLK1 (5-20mU diluted in 50mM Tris pH 7.5, 0.1mM EGTA, 0.1% b-mercaptoethanol, 
1mg/mL BSA, 100µM vanadate) was assayed against a substrate peptide 
(ISDELMDATFADQEAKKK) in a final volume of 25.5µL containing 50mM Tris pH 
7.5, 300µM substrate peptide, 10mM magnesium acetate, 0.05% b-mercaptoethanol, 
10µM vanadate and 0.005mM [33P-g-ATP] (50-1000 cpm/pmole) and incubated for 30 
min at room temperature. Assays were stopped by addition of orthophosphoric acid (5µL 
0.5M; 3%) and then harvested onto P81 unifilter plates with a wash buffer of 50mM 
orthophosphoric acid. Concentrations of JB tested were 0.5, 1, 5, 10, 50µM. 
 
2.16 In silico pharmacokinetic analyses 
All predictions for both JB and JBA were conducted using GastroPlusTM version 9.0.0007 
with built-in ADMET Predictor version 7.2.0.0 module. The input parameters for the 
simulations are shown in supplementary information (Suppl Table 1). In silico 
predictions of physicochemical and pharmacokinetic properties were performed based on 
the chemical structures of the two compounds by GastroPlusTM. Built-in physiologically 
based pharmacokinetic (PBPK) models of relevant species were used for simulation of 
the pharmacokinetic profiles. Plasma concentration-time profiles following intravenous 
bolus injection and oral administration were predicted in mice and humans. For oral 
administration, PBPK models of fed state were applied for the predictions. 
  
 
2.17 Statistical analyses 
Experiments were conducted >3 times; with representative experiments demonstrated. 
One-way and two-way analysis of variance (ANOVA) were used to determine statistical 
significance. The minimal level of significance (p<0.05) was determined using Dunnett’s 
multiple comparison tests. 
 
3. Results 
 
3.1 MTT assay 
Both JB and JBA revealed potent growth inhibitory activity against five cell lines (Fig. 2; 
Table 1).  GI50 values for JB were between 0.7 - 0.9µM for HCT-116, A549 and MCF-7. 
However, JBA exhibited more potent growth inhibitory activity against HCT-116, A549 
and MCF-7 than JB with GI50 values ranging between 0.36 – 0.6µM. MIA PaCa-2 cells 
showed greatest sensitivity to JB and JBA with GI50 values  0.25µM. 2-Way ANOVA 
between control and treatment groups revealed significant (p<0.01) growth inhibition by 
JB concentrations >0.1µM in HCT-116, A549 and MCF-7 and > 0.05µM in MIA PaCa-2 
cells. JBA >0.1 µM significantly inhibited (p<0.01) growth in all cell lines. DMSO had 
no effect on absorbance readings for all cell lines (data not shown).  
6 
 
 
3.2 Cell counts 
Cell counts were performed following 72h exposure of HCT-116 and MIA PaCa-2 cells 
to JB to validate MTT assay results. Dose-dependent reductions in cell numbers were 
particularly evident between 200nM and 500nM JB. At 1µM, JB caused cytotoxicity as 
significantly fewer cell numbers were recorded than were initially seeded (Figure 2 E and 
F; p<0.01). 
 
3.3 Effect of JB and JBA on HCT-116 Colony Formation 
Both JB and JBA significantly inhibited colony formation after 24h treatment of cells at 
concentrations equivalent to 1×GI50 and 2×GI50 (Fig. 3A). JB inhibited colony formation 
in A549 cells at 1×GI50 and 2×GI50 values by 64% and 80% respectively. Although MCF-
7 and MIA PaCa-2 showed different sensitivity to JB (GI50 values 0.91 μM and 0.25 μM 
respectively), colony formation was similarly inhibited (by 95% and 99%) at 1×GI50 and 
2×GI50 values respectively. Complete (100%) inhibition of colony formation was 
observed in HCT-116 cells exposed to 1× and 2×GI50 JB, reflecting potency and 
cytotoxicity of JB (Fig. 3B). JBA showed significant and dose-dependent inhibition; 
interestingly, inhibition of colony formation by JBA in HCT-116 and MCF-7 was less 
potent than JB. At 1×GI50 and 2×GI50 values, JBA inhibited colony formation in HCT-
116 by 40% and 96% respectively and in MCF-7 by 66% and 80% respectively. JBA 
revealed inhibitory effects similar to JB in MIA PaCa-2 cells (> 95% and 99% at 1×GI50 
and 2×GI50 respectively). 
 
3.4 Cell cycle analysis 
MTT and clonogenic assays suggest that JB compromises cancer cell growth and 
viability. Guided by these observations, we investigated the effect of JB on cell cycle 
perturbation by flow cytometry. Cells, treated with JB at 1×GI50 and 2×GI50 for either 24, 
48 or 72h. Stark G2/M cell cycle arrest was observed following 24 h exposure to JB in 
HCT-116, MCF-7 and A549 at 1×GI50 and 2×GI50 (Fig. 4). Profound G2/M accumulation 
was sustained after 48h and 72h in HCT-116, MCF-7 and A549 cells at 1×GI50 and 
2×GI50 with time-dependent accumulation of HCT-116 and A549 events in pre-G1 at 1× 
and 2×GI50. The most sensitive cell line indicated by MTT assay, MIA PaCa-2, revealed 
significant cell cycle arrest in G2/M phase at 2×GI50 at 24h and 48h (Fig. 4). 
Interestingly, a significant pre-G1 was observed, earlier in MIA PaCa-2, following 24h 
exposure and sustained up to 72h at 2×GI50. Cell cycle profiles are shown in 
supplementary Fig. 1. 
 
3.5 JB inhibits tubulin polymerisation  
Profound G2/M cell cycle arrest led us to investigate the effect of JB on tubulin 
polymerisation and compare effects to tubulin-stabilising and destabilising agents 
paclitaxel and nocodazole respectively (Fig. 5). Paclitaxel (5μM) induced rapid 
polymerisation of tubulin. In contrast, 5μM nocodazole arrested tubulin polymerisation. 
The effect of JB on tubulin polymerisation was unequivocal and similar to nocodazole: 
JB comprehensively inhibited tubulin polymerisation at 1 and 5μM. 
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3.6 JB induces apoptosis in cancer cells 
Annexin-V/PI apoptosis and caspase-3 activation assays were performed to investigate 
apoptosis-inducing properties of JB in HCT-116, A549 and MIA PaCa-2 cell lines 
exposed to JB (1 and 2 × GI50; 24, 48 and 72h). Apoptotic populations were confirmed by 
dual annexin V-FITC/PI staining (supplementary Fig. 2). JB revealed profound time-
dependent incidence of apoptosis. JB induced significant (p<0.01) early (A+/PI-) and late 
(A+/PI+) HCT-116 apoptosis at 1× and 2×GI50 following 24, 48 and 72 h exposure (Fig. 
6A). A549 revealed significant (p<0.01) apoptosis in the presence of JB at 1× and 2×GI50 
after 48 and 72h treatment (Fig. 6B). On the other hand, the most sensitive cell line to JB 
(MIA PaCa-2), indicated by MTT, appeared more resistant to apoptosis at 1×GI50. 
However, MIA PaCa-2 showed significant (p<0.01) early and late apoptosis at 2×GI50 
concentration (Fig. 6C). The highest percentage apoptosis at 2×GI50 was observed in 
HCT 116 cells after 72h exposure to JB (50±4.71 %), compared to MIA PaCa-2 (45±4.74 
%) and A549 (34±1.62 %). Induction of caspase-3/7 activity was measured in HCT-116, 
VR HCT-116 and MIA PaCa-2 cells after exposure to either JB or vincristine at 1×GI50 
for 48h (Fig. 6D). JB evoked significantly (p<0.01) increased caspase activity in all three 
cell lines (HCT-116 230%, VR HCT-116 150% and MIA PaCa-2 155%) compared to 
control (100%). Vincristine clearly increased caspase activity in HCT-116 (200%) and 
MIA PaCa-2 (180%), in contrast, no enhanced activity was detected in VR HCT-116 
cells. 
 
3.7 JB alters protein expression 
Western blot was used to investigate expression of proteins possessing roles in mitosis, 
apoptosis and cell survival. Lysates of HCT-116 and MIA PaCa-2 cells following 72h 
exposure of cells to 1× and 2× GI50 JB were prepared. Down-regulation of PLK1 and β-
tubulin was observed after exposure to JB for 72h. Dose-dependent elevation in cleaved 
PARP accompanied reduction in expression of anti-apoptotic/pro-survival proteins Mcl-1 
and Bcl-2 (Fig. 7A and B).  
 
3.8 JB causes severe disruption in cytoskeletal architecture 
Based on the ability of JB to inhibit microtubule assembly, prior to induction of apoptosis 
confocal microscopy was conducted to determine cellular changes in cytoskeletal 
architecture. Images were captured after 24 h exposure of HCT-116 cells to 1×GI50 JB or 
vincristine or vehicle alone. Representative images (Fig. 8) reveal the effect of JB on cell 
morphology. JB caused multinucleation (1) nuclear fragmentation (2) and membrane 
blebbing (3). Multipolar spindles were also evident in cells treated with JB and 
vincristine (4).  
 
3.9 Generation of vincristine resistant (VR HCT-116) cells 
A variant cell line possessing >300-fold resistance to vincristine was generated from 
HCT-116 cells. Cells were initially exposed to 5nM vincristine. Drug concentrations 
were escalated stepwise over 6 months until VR HCT-116 cells, able to survive 
subculture in the continued presence of 2μM were established. Vincristine GI50 values 
were as follows: HCT-116, 5nM; VR HCT-116, 1.64 μM. Western blot determined 
expression of the ATP binding cassette protein ABCB1, P-glycoprotein (Pgp), product of 
the multi-drug resistance (MDR1) gene in VR HCT-116 (Fig. 7). In contrast to 
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vincristine, JB and JA retained activity in VR HCT-116 cells, demonstrating ability to 
overcome Pgp efflux; GI50 values <700 nM JB were obtained in HCT-116 and VR HCT-
116 (Table 2). 
 
3.10 JB induces ROS production in cancer cells 
Production of ROS was measured in HCT-116, VR HCT-116 and MIA PaCa-2 cells 
following treatment with either JB or vincristine at 1×GI50 following exposure for 24h 
(Fig. 9). JB evoked significantly increased ROS production in HCT-116 (348%), VR 
HCT-116 (170%) and MIA PaCa-2 (281%) following 24h. Vincristine showed clear 
increase in ROS production in HCT-116 (239%) and MIA PaCa-2 (277%). Consistent 
with caspase-3 activity assay, vincristine failed to induce ROS in VR HCT-116 cells. 
 
3.11 JB potently inhibits the activity of PLK1  
JB significantly (p<0.05) and dose-dependently inhibited PLK1 activity (0.5, 1, 5, 10 and 
50µM; Fig. 10; IC50 1.5 µM). In addition, in cells exposed to JB (1× and 2×GI50) down-
regulation of PLK1 expression was detected (Fig. 7A and B). 
 
3.12 Predicted pharmacokinetic profiles of JB and JBA 
In silico simulations by GastroPlusTM predicted pharmacokinetic profiles for JB and JBA. 
The plasma concentration-time profiles for both compounds in humans and mice (the 
species commonly used for preclinical efficacy studies) are shown in Fig. 11. While both 
JB and JBA were predicted to have relatively high oral bioavailability (>70%) without 
major species differences, higher oral bioavailability was revealed for JB than JBA 
(Table 3). The elimination rate of JBA was higher than that of JB, which may be a 
consequence of JBA`s rapid conversion to JB. 
Predictions to predetermine the therapeutic doses needed for future preclinical efficacy 
studies were performed in mice with unbound plasma concentration of the compounds, 
because it will be the unbound fraction of the compounds that exert pharmacodynamic 
activities in vivo. Also, fed state was applied because the mice are likely to be in fed state 
during preclinical efficacy studies where multiple dosing will be applied. Unbound 
plasma concentration-time profiles were plotted together with the GI50 values obtained 
from in vitro experiments to provide preliminary prediction of efficacious doses. From 
Fig. 12, it can be seen that dose-linear pharmacokinetics are expected from the dose range 
simulated (2-64 mg/kg). As a result, doses of 8-16 mg/kg are predicted to be able to 
maintain the unbound plasma concentrations of both compounds above the GI50 values 
for most cell lines in mice during efficacy studies.  
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4. Discussion  
JB a novel aspidosperma indole alkaloid and its acetate derivative revealed profound 
growth inhibitory and cytotoxic activity against human-derived HCT-116, VR HCT-116, 
MCF-7, A549 and MIA PaCa-2 cancer cell lines. Generally, JBA exhibited greater 
potency against HCT-116, A549 and MCF-7 than JB in the MTT assay. JBA’s enhanced 
potency may be attributed to its stability when compared to JB, which may undergo 
hydrolysis and degradation thereby impacting activity [8]. Additionally, the presence of 
an acetate group reduces overall polarity possibly facilitating compound diffusion across 
hydrophobic cell membranes [26]. Therefore enhanced intracellular concentrations of 
JBA may be achieved, leading to slightly higher potency. Interestingly, JB possessed 
greater activity in most cell lines tested when compared to JA notably against A549; GI50 
JB  0.7 μM; GI50 JA 3.7 μM [8]. JB possesses an epoxide moiety which may confer 
enhanced activity over JA [8]. Subsequent cell counts, performed following 72 h 
exposure of cells to JB, corroborated potent growth inhibitory properties detected by 
MTT assay. Estimated JB and JBA GI50 values, calculated from MTT assays were used 
in subsequent assays. JB and JBA (24h exposure) significantly inhibited HCT 116, MCF-
7, MIA PaCa-2 and A549 colony formation (Fig. 3A). These outcomes indicate that cells 
have either been killed or have lost their ability to proliferate and form progeny colonies 
(Fig. 3B). In contrast, the effect of JA on MCF-7 colony formation at 1 × GI50 was not 
significant, thus exposure of MCF-7 to 1×GI50 JA for 24 h was not sufficient to cause 
cytotoxicity or inhibit proliferation [8]. Although, JBA showed potent growth inhibitory 
activity in MTT assays compared to JB after 72h continued treatment, reduced potency 
against HCT-116, MCF-7 and MIA PaCa-2 in clonogenic assays was observed after 
exposure for 24h (Fig. 3A). JBA may act as a prodrug requiring the presence of cellular 
esterases for bio-activation [26]. Because of the low cell densities seeded in clonogenic 
assays, there may be insufficient esterase activity to catalyse enzymatic hydrolysis. 
Indeed, incomplete or slow bioconversion of prodrugs can lead to lower than predicted 
bioavailability [26]. JB evoked significant G2/M arrest (Fig. 4); at 2×GI50 JB was able to 
sustain significant G2/M arrest throughout the 72h exposure. It was hypothesised that JB 
like analogue JA may perturb microtubule dynamics underpinning G2/M halt. Many 
drugs show similar inhibitory activity on the cell cycle, e.g. taxanes, vinca alkaloids, 
nocodazole and colchicine. These drugs act as microtubule-disrupting agents and block 
the cell cycle at G2/M through interference with tubulin (de)polymerisation and 
microtubule (dis)assembly [27]. Tubulin polymerisation was carried out in the presence 
of paclitaxel, nocodazole, JB (1 and 5μM) or vehicle alone. Paclitaxel was used as a 
positive control (microtubule stabiliser), while nocodazole, a negative control, inhibits 
tubulin polymerisation and destabilises microtubules. JB unambiguously and 
comprehensively inhibited tubulin polymerisation (Fig. 5). In addition, significant 
reduction in expression of β-tubulin protein in JB-treated cells further inferred JB may 
induce microtubule disarray (Fig. 7B).  Confocal microscopy following treatment of cells 
with JB and vincristine was undertaken; DNA and tubulin were stained to accentuate 
changes in cytoskeletal architecture and cell morphology triggered by these agents. 
Treatment of tumour cells with MTAs is responsible for features characteristic of failed 
polymerisation including multipolar spindles and irregular chromosome segregation in 
addition to apoptotic signs such as DNA fragmentation and blebbing [28, 29]. Confocal 
microscopy images of JB-treated cells revealed such features. Multipolar spindles and 
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misaligned chromosomes were evident (Fig. 8); multinucleation (aneuploidy), nuclear 
fragmentation and membrane blebbing were also detected. It has emerged that like the 
vinca alkaloids; JB caused G2/M cell cycle arrest, overwhelmingly inhibited tubulin 
polymerisation and caused microtubule disarray leading to formation of multipolar 
spindles. In addition, jerantinine analogues share structural similarity with vincristine; 
cross-resistance between these alkaloids was therefore investigated. We endeavoured to 
generate variant HCT-116 cell lines displaying acquired resistance to vincristine or 
jerantinine. After 6 months in the presence of escalating vincristine concentrations, VR 
HCT-116 cells evolved which survived and proliferated in medium spiked with 2μM 
vincristine. VR HCT-116 cells were >300-fold more resistant to vincristine than HCT-
116 cells. In contrast, VR HCT-116 cells were slightly more sensitive than parent HCT-
116 cells to JB and JA (Table 2). Western blot analysis determined expression of P-
glycoprotein (Pgp) in VR HCT-116 (Fig. 7A). Cell membrane Pgp is an efflux pump of 
the ATP-binding cassette (ABC) class, it exports drugs to the extracellular environment 
and is associated with multidrug resistance [30]. Expression confers resistance not only to 
vincristine, but to multiple chemotherapeutic agents possessing structural diversity and 
distinct modes of action. Clinically, Pgp expression is an immense problem limiting 
treatment success and cancer survival. Thus discovery of a novel alkaloid which appears 
not to be a Pgp substrate, able to evade multiple drug resistance is encouraging; however, 
it should be cautioned that agents able to evade ATP binding cassette pumps may by 
cyto- and neurotoxic; thus future research endeavours could include investigation of 
targeted delivery systems for such molecules. Intriguingly, following 2 years of 
continuous efforts, we have been unable to generate a variant HCT-116 cell line with 
acquired resistance to jerantinine. The effect of JB on activity of additional proteins 
which possess critical roles in mitoses were examined. Human PLK1, a member of the 
serine/threonine family of kinases is an important enzyme in control of progression 
mitosis, and maintenance of genomic integrity [31, 32]. PLK1 regulates multiple cell 
cycle-related events, including cdc2 activation, centrosome maturation, chromosome 
segregation, formation of bipolar spindle and execution of cytokinesis [33]. Substantially 
elevated expression of PLK1 has been reported in solid malignancies compared to 
healthy tissue [31, 32], leading to its classification as an oncogenic kinase. PLK1 has 
been proposed as a novel diagnostic and poor prognostic marker, and is a validated 
therapeutic target for cancer [33]. In preclinical studies, small interfering RNA molecules 
that inhibit PLK1 inhibited cancer cell proliferation and tumour growth, causing mitotic 
arrest and apoptosis [34]. Small molecule PLK1 inhibitor B12536 inhibited the self-
renewal of cancer cells with high PLK1 expression [35, 36]. JB caused dose-dependent 
reduction in PLK1 activity (IC50 1.5µm; Fig. 10) and down-regulated PLK1 expression in 
treated cells (Fig. 7B). This provides supportive evidence that, although comparable to 
vincristine in ability to disrupt microtubules, JB may interact upstream of tubulin via 
PLK1, which may be one of multiple possible targets that contribute to G2/M arrest.  
Like vincristine, JB significantly increased ROS production in HCT-116 and MIA PaCa-
2 cells (Fig. 9). The source of ROS may be enzymatic (NADPH oxidase, cytochrome 
P450s for example) or non-enzymatic (mitochondrial respiratory chain). ROS may be 
formed as by-products of metabolism of oxygen-containing compounds; enzyme-
catalysed reactions that generate ROS include those metabolising vinca alkaloids (and 
possibly jerantinines). Vinca alkaloids also promote release of cytochrome C from 
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mitochondria inducing cell death and interfere with the electron transport chain resulting 
in production of superoxide radicals [37, 38, 39]. Beyond the scope of this study, we 
hypothesise that jerantinines may generate ROS through both these routes. Natural 
product anticancer agents such as vincristine and taxanes can induce apoptosis via ROS 
production [40]. The greater sensitivity of some tumour cells (over normal cells) to 
oxidative stress is considered a therapeutic option for new anticancer drugs [40]. Arsenic 
derivatives are examples of compounds that elicited anticancer activity and apoptotic 
effects by production of high levels of ROS [40]. ROS may be responsible for initiating 
caspase activation [41]. Through oxidation of mitochondrial pores, ROS may cause 
release of cytochrome c which plays an important role in caspase activation and induction 
of apoptosis [41]. Furthermore, through ROS production, MTAs may modulate 
microtubule dynamics through EB1 phosphorylation and lead to anti-proliferative and 
anti-migratory effects [42]. In VR HCT-116 cells, only JB caused a significant rise in 
ROS, again demonstrating that JB overcomes Pgp-mediated vincristine (and multi-drug) 
resistance. These data, consistent with MTT results (Table 2), support the thesis that the 
mechanism of antitumour action of JB involves generation of ROS. Inhibition of 
microtubule assembly and failed mitoses may lead to a number of consequences, 
including aneuploidy and apoptosis [43, 44]. PLK1 inhibition and ROS induction, as 
discussed, may also precede apoptosis. At 72 h HCT-116, MIA PaCa-2, and A549 cells 
exhibited a significant (p<0.01) increase in pre-G1 events following treatment with JB 
(Fig. 4). Interestingly, MCF-7 did not show significant elevation in pre-G1 events, 
because MCF-7 cells do not express caspase 3 [45]. Pre-G1 events are an indication of 
DNA cleavage by DNAase enzymes, an event integral to apoptosis [8]. Annexin-V/PI 
apoptosis and caspase-3 activation assays were used to confirm these observations. After 
72h JB elicited time- and dose-dependent HCT-116, MIA PaCa-2, and A549 apoptosis 
(Fig. 6). Clear induction of caspase 3 activity was revealed in HCT-116, VR HCT-116 
and MIA PaCa-2 cells at 1×GI50 following 48h exposure to JB, while vincristine 
precipitated significantly increased caspase activity in HCT-116 and MIA PaCa-2 but not 
VR HCT-116 cells (Fig. 6D). Concomitant with caspase activation, cleaved PARP was 
observed in A549 (data not shown), HCT-116 and MIA PaCa-2 cells exposed to JB. 
Corresponding down-regulation of anti-apoptotic/pro-survival proteins Mcl-1and Bcl-2 
(Fig. 7A and B) were also detected. Cancers commonly express elevated levels of anti-
apoptotic oncogenic Bcl-2 family members. Their down-regulation diminishes cancer cell 
survival. Taken together, morphological features characteristic of apoptosis (e.g. 
membrane blebbing), exposure of phosphatidylserine on the cell membrane exterior, 
reduced Mcl-1 and Bcl-2 expression, caspase activation and cleaved PARP strongly 
suggest a cellular apoptotic destiny. In summary, JB elicited potent anti-proliferative 
effects and significantly inhibited colony formation in human-derived carcinoma cell 
lines. Profound G2/M cell cycle arrest and inhibition of tubulin polymerisation was 
demonstrated. JB inhibited PLK1 activity and significantly increased ROS production in 
treated cancer cells, ultimately inducing apoptosis. Intriguingly, JB retained sensitivity in 
VR HCT-116 cells expressing Pgp. The ability to generate a corresponding HCT-116 
variant cell line resistant to jerantinine was however elusive; we postulate that JB`s 
multiple targets, which possess key roles in tumourigenesis, preclude (to date) evolution 
of jerantinine resistance compatible with cell viability, and conclude that further 
preclinical evaluation of these novel alkaloids is justified.  
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Thus, in silico preclinical biopharmaceutical evaluation of JB and JBA were performed 
using GastroPlusTM, a powerful tool used in drug discovery programmes for lead 
optimisation and compound selection [46, 47]. The built-in generic PBPK models have 
provided predictions for a wide range of drugs [48, 49, 50] and there are numerous 
reports where GastroPlusTM has successfully predicted pharmacokinetic profiles in 
preclinical species and humans [51]. Predictions can be made based on chemical structure 
and/or physicochemical properties [52, 53, 54, 55]. In the present study, calculations by 
GastroPlusTM were based on the chemical structure of JB and its acetate derivative; rapid 
absorption and bioavailability values >70% were predicted for both compounds. 
Predictions to predetermine the doses needed for preclinical efficacy studies were 
performed in mice: doses of 8-16 mg/kg would be expected to maintain the unbound 
plasma concentrations of both compounds above the GI50 values for most cell lines. 
These data provide useful guidelines for future preclinical and clinical evaluation.  
This new natural indole alkaloid, which targets mechanisms pertinent to tumourigenesis 
and cancer cell survival is worthy of continued development for treatment of malignant 
disease. 
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Figure legends. 
 
Fig.1 The structures of jerantinine B and jerantinine B acetate 
 
Fig. 2 Growth inhibitory effects of JB and JBA on HCT-116 (A), MCF-7 (B), A539 (C) and MIA PaCa-2 
cell lines (D). Cells were seeded at a density of 3×103 cells/well in 96-well plates and incubated for 72h 
(n=8,  3 trials). Effects of JB on HCT-116 (E) and MIA PaCa-2 (F) cell numbers. Cells (2×104 cells/well) 
were seeded in 6 well plates are incubated overnight before treatment with JB at 0.1, 0.2, 0.5 and 1µM 
(72h). Cells were harvested and counted by haemocytometer.   
 
Fig. 3A Mean survival fraction (%) of treated cells as a percentage of the control population for A549, 
HCT-116, MCF-7 and MIA PaCa-2 with SEM. JB exhibited significant reduction in colony formation 
(p<0.01, n=2 for each of the 2 trials). B Representative photograph showing effect of JB on HCT-116 
colony formation at 1×GI50 and 2×GI50 
 
Fig. 4 Effect of 1xGI50 and 2xGI50 JB following 24, 48 and 72h exposure on HCT-116 (A), A549 (B), 
MCF-7 (C) and MIA PaCa-2 (D) cell cycle. JB evoked significant arrest in G2/M phase ( p<0.05, n=2; 
experiments were repeated ≥3 times) 
 
Fig. 5 Effect of JB (1μM and 5μM) on tubulin polymerisation. Paclitaxel and nocodazole (5μM) were used 
as positive and negative controls respectively. JB strongly inhibited tubulin polymerisation.  
 
Fig. 6A, B and C Effects of JB on HCT-116, A549 and MIA PaCa-2 apoptosis. Cells were treated with 1x 
and 2xGI50 JB for 24, 48 and 72h. Annexin-V/PI apoptosis assay was adopted to determine the percentage 
apoptotic cells. Total apoptosis comprises early apoptotic (annexin V-positive) and late apoptotic (annexin 
V-positive and PI positive) populations. Fig. 6D Effect of JB on caspase 3/7 activity in HCT-116,VR HCT-
116 and MIA PaCa-2cells after 48h exposure to 1×GI50. Mean± SEM 3 independent trials (n=2 per trial).  
 
Fig. 7A Protein expression in HCT-116 and MIA PaCa-2 lysates following 72h exposure of cells to JB. 
Lysates containing 50µg protein were loaded into each well and proteins separated by SDS-PAGE. Western 
blots were performed using antibodies to detect whole and cleaved PARP, Mcl-1, Bcl-2, PLK1, TUBB, 
Pgp and housekeeping gene GAPDH. HCT-116 and MIA PaCa-2 cells were treated at 1×GI50 and 2 × GI50.  
 
Fig. 7B Collated densitometric measurement of protein expression levels PARP cleavage was observed at 
1×GI50 and was accompanied by a dose-dependent decrease in Mcl-1 and Bcl-2. PLK1 and TUBB down-
regulation was observed in HCT-116 and MIA PaCa-2 cells. GAPDH was used as an internal loading 
control. Expression of Pgp was observed in VR HCT-116. Mean± SD ≥3 independent trials. 
 
Fig. 8 Effects of JB and vincristine (24h exposure) on HCT-116 cell morphology. 1st row (A,B,C,D): 
controls with vehicle only; 2nd row (E,F,G,H): JB (1xGI50 = 0.7µM); 3rd row (I,J,K,L): vincristine (1xGI50 
= 5nM). JB caused multinucleation (1) nuclear fragmentation (2) and blebbing (3). Multipolar spindles 
were also evident in samples treated with JB and vincristine (4). Experiments were repeated 3 times. 
 
 
Fig. 9 JB (24h) potently increased ROS production in HCT-116, VR HCT-116 and MIA PaCa-2 cells 
compared to vincristine which caused ROS production in HCT-116 and MIA PaCa-2 cells only. Cells were 
treated with JB (1xGI50 = 0.7µM) or vincristine (1xGI50 = 5nM). Mean± SEM 3 independent trials (n=2 
per trial) 
 
Fig. 10 Dose-dependent inhibition of PLK1 activity by JB. Mean±SD was calculated of two independent 
trials (n=2 per trial). 
 
Fig. 11 Predicted plasma concentration-time profiles. (A) Prediction after administration of 4 mg/kg of JB 
to mice. (B) Prediction after administration of 100 mg capsule of JB to 70 kg humans. (C) Prediction after 
administration of 4 mg/kg of JBA to mice. (D) Prediction after administration of 100 mg capsule of JBA to 
70 kg humans. 
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Fig. 12 Predicted unbound plasma concentration-time profiles plotted with GI50 values obtained from MTT 
assays. (A) Prediction after oral administration of JB in mice and GI50 values of JB on various cancer cell 
lines. Curves in grayscale from top to bottom represent unbound plasma concentration-time profiles after 
oral administration at doses of 64, 32, 16, 8, 4 and 2 mg/kg, respectively. Straight lines in colour scheme 
from top to bottom represent GI50 values from MRC-5, MCF-7, A549, HCT-116, VR HCT-116 and MIA 
PaCa-2 cell lines, respectively. (B) Prediction after oral administration of JBA in mice and GI50 values of 
JBA on various cancer cell lines. Curves in grayscale from top to bottom represent unbound plasma 
concentration-time profiles after oral administration at doses of 64, 32, 16, 8, 4 and 2 mg/kg, respectively. 
Straight lines in colour scheme from top to bottom represent GI50 values from A549, MCF-7, HCT-116 and 
MIA PaCa-2 cell lines, respectively.  
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Table 1. Effect of JB and JBA on growth of human-derived cancer cells 
Mean GI50 values (M) 
 
Breast 
carcinoma 
MCF-7 
 
Lung 
carcinoma 
A549 
 
Pancreas 
carcinoma 
MIA PaCa-2 
 
Colon 
carcinoma 
HCT-116 
 
Human foetal 
lung fibroblast 
MRC-5 
 
JB 0.917±0.004 0.701±0.010 0.245±0.033 0.682±0.026 1.915±0.036 
JBA 0.482±0.009 0.547±0.092 0.253±0.010 0.362±0.006  
MTT assay, following 72 h exposure of cells to test agents. Mean  SD GI50 values (M) values from  3 independent 
trials where n = 8
 
 
 
Table 2. Effect of JB, JA and vincristine on growth of wild type and VR HCT-116 cells 
Mean GI50 values (M) 
 
 
Designation JB JA Vincristine 
 
Wild colon carcinoma 
 
HCT-116 
 
0.682±0.026 
 
0.762±0.13 
 
0.005±0.001 
 
Vincristine resistant 
colon carcinoma 
 
VR HCT-116 
 
0.490±0.015 
 
0.438±0.1 
 
1.64±0.45 
MTT assay, following 72 h exposure of cells to test agents. Mean  SD GI50 values (M) values from  3 independent 
trials where n = 8
 
 
Table 3. Species differences in input values and predicted outcomes for JB and JBA 
  
JB   JBA 
Mouse Human 
 
Mouse Human 
Body weight (kg) 0.025 70 
 
0.025 70 
Dose (mg) 1 100 
 
1 100 
Dose volume (mL) 0.25 250 
 
0.25 250 
Formulation Solution Capsule 
 
Solution Capsule 
CLh (L/h/kg) 0.44 0.12 
 
1.48 0.42 
CLr (L/h/kg) 0.03 0.01 
 
0.04 0.01 
t1/2 (hr) 1.25 5.88 
 
0.297 1.827 
F (%) 92.0 90.9   77.6 74.4 
CLh, hepatic clearance; CLr, renal clearance; t1/2, elimination half-life; F, oral bioavailability. 
 
 
 
